NASDAQ:IVA - Nasdaq - US46124U1079 - ADR - Currency: USD
NASDAQ:IVA (6/2/2025, 8:11:09 PM)
3.39
0 (0%)
The current stock price of IVA is 3.39 USD. In the past month the price decreased by -3.14%. In the past year, price decreased by -4.24%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.21 | 330.30B | ||
AMGN | AMGEN INC | 13.9 | 155.11B | ||
GILD | GILEAD SCIENCES INC | 14.07 | 135.48B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.39B | ||
REGN | REGENERON PHARMACEUTICALS | 11.08 | 52.99B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.91B | ||
ARGX | ARGENX SE - ADR | 101.67 | 35.70B | ||
BNTX | BIONTECH SE-ADR | N/A | 27.19B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.3 | 26.59B | ||
NTRA | NATERA INC | N/A | 21.94B | ||
BIIB | BIOGEN INC | 8.29 | 19.22B | ||
UTHR | UNITED THERAPEUTICS CORP | 12.99 | 14.68B |
Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. The company is headquartered in Daix, Occitanie and currently employs 109 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
INVENTIVA SA - ADR
50 rue de Dijon, Daix
Daix OCCITANIE 21121 FR
CEO: Frederic Cren
Employees: 116
Phone: 33380447500
The current stock price of IVA is 3.39 USD.
The exchange symbol of INVENTIVA SA - ADR is IVA and it is listed on the Nasdaq exchange.
IVA stock is listed on the Nasdaq exchange.
11 analysts have analysed IVA and the average price target is 9.95 USD. This implies a price increase of 193.39% is expected in the next year compared to the current price of 3.39. Check the INVENTIVA SA - ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
INVENTIVA SA - ADR (IVA) has a market capitalization of 471.34M USD. This makes IVA a Small Cap stock.
INVENTIVA SA - ADR (IVA) currently has 116 employees.
INVENTIVA SA - ADR (IVA) has a support level at 3.14 and a resistance level at 3.4. Check the full technical report for a detailed analysis of IVA support and resistance levels.
The Revenue of INVENTIVA SA - ADR (IVA) is expected to grow by 134.71% in the next year. Check the estimates tab for more information on the IVA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
IVA does not pay a dividend.
INVENTIVA SA - ADR (IVA) will report earnings on 2025-07-29.
INVENTIVA SA - ADR (IVA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.62).
The outstanding short interest for INVENTIVA SA - ADR (IVA) is 0.97% of its float. Check the ownership tab for more information on the IVA short interest.
ChartMill assigns a technical rating of 5 / 10 to IVA. When comparing the yearly performance of all stocks, IVA turns out to be only a medium performer in the overall market: it outperformed 56.4% of all stocks.
ChartMill assigns a fundamental rating of 1 / 10 to IVA. IVA has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months IVA reported a non-GAAP Earnings per Share(EPS) of -1.62. The EPS decreased by -20.47% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -154.84% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 87% to IVA. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 56.03% and a revenue growth 134.71% for IVA